Menu
Recruiting NCT06155916

Sleep and Neuropathic Pain - Intervention Study on Pregabalin

No phase Interventional Neuropathic Pain Insomnia Sleep Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Pregabalin.
Who it may be relevant to
Registry conditions: Neuropathic Pain, Insomnia, Sleep Disorder. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Finland
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Sleep Structure in Neuropathic Pain Patients, Psychological Factors, Brain Connectivity, and the Effect of Pregabalin on Sleep and Pain

Overview

The goal of this clinical study is to study sleep and its microstructure in neuropathic pain patients who have or who do not have a clinically significant sleep disturbance, before and during (after 1-month stabile dosage) pregabalin treatment. To find out whether reduced pain by pregabalin associates with improved sleep quality; to study, using resting state fMRI, brain network connectivity and the volume of the choroid plexus before and during pregabalin treatment (after dosage stable for one month) at baseline and during stabile treatment with pregabalin, and to compare the usability and reliability of sleep-related information collected with sleep diaries, actigraphy, iButtons, and ambulatory polysomnography in peripheral painful neuropathy patients. The main questions it aims to answer are: * Is pregabalin more efficacious in neuropathic pain patients who suffer from insomnia compared to those with no clinically meaningful sleep disturbance? * Does sleep disturbance due to pain associate with brain network connectivity and may these changes be reversed by pregabalin treatment? Participants will * Fulfill e-questionnaires and keep sleep diary before and after 1month stabile pregabalin intervention * Before and after 1-month stabile pregabalin medication: 1-week Actiwatch monitoring, iButton (1 day and night), ambulatory polysomnography (1 night), brain fMRI. Researchers will compare patients with high ISI score patients to see if they benefit more from pregabalin treatment than those with low ISI score.

Detailed description

This is a clinical study to analyze sleep and pain and their response to pregabalin in 40 patients aged 18 to 75 years with chronic (duration\>3 months) moderate to severe pain (NRS ≥ 4/10) due to peripheral neuropathy. The investigators divide patients to two groups according to scores in ISI: the ones with clinically significant insomnia with score 15 or more (ISI High) and the ones without marked insomnia with score 14 or lower (ISI Low). Sleep will be assessed by a sleep diary, iButton, polysomnography and 1-week Actiwatch monitoring before and after 1-month stabile pregabalin dosage. Additionally, at these time points, several questionnaires regarding pain, sleep, mood, and quality of life and functional brain MRI will be performed. At pregabalin administration, the dose is added three to four day intervals, if tolerated by the patient. After a maximum tolerated dose has been stable for 1 month, the sleep studies, questionnaires, and brain fMRI are repeated. The study duration is about 3 months.

Interventions

  • Drug Pregabalin
    Pregabalin administration and titration to the highest dosage that the patient tolerates. The patient continues with the highest dose for one month and the pre-intervention studies are repeated.

Primary outcome measures

  • Pregabalin response to pain [Time frame: Change from baseline pain intensity and interference immediately after the intervention]
  • Pregabalin effect on sleep stages [Time frame: Change from baseline immediately after the intervention]
  • Sleep disturbance associations to brain network connectivity [Time frame: Change from baseline immediately after the intervention]
  • Sleep disturbance associations to choroid plexus volume in brain fMRI [Time frame: Change from baseline immediately after the intervention]
  • Pregabalin effect on circadian rhythms [Time frame: Change from baseline immediately after the intervention]
  • Pregabalin effect on body temperature during sleep [Time frame: Change from baseline immediately after the intervention]

Eligibility criteria

Inclusion criteria

  • Chronic (duration > 3 months) painful peripheral neuropathy
  • Pain moderate to severe (NRS ≥ 4/10) during the past week

Exclusion criteria

  • psychotic depression, clinically significant bipolar disorder
  • contraindication for performing brain fMRI (metal in the body etc)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Finland · 2 centers
  • Helsinki University Central Hospital — Helsinki
  • Helsinki University Hospital, Department of Neurology — Helsinki

Identifiers

NCT: NCT06155916 · TYH2020214

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗